top of page
GLOBAL BIOSCIENCES DEALMAKERS: 30+ YEARS. 300+ CLIENTS & DEALS. BILLIONS IN VALUE.
Sage Group News
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of enrollment in the SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery. This milestone follows recommendation by the independent Data Safety Monitoring Board (“DSMB”),
Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody
Starrygene ( https://www.starrygene.com/ ) is a clinical stage biotechnology company based in China, focused on XMVA09, a novel...
Opportunity to License SP16, A Novel Treatment For Acute Kidney Injury (AKI)
Serpin Pharma (“Serpin”) is an anti-inflammatory/immunology company focused on developing its patented (CoM and use) SP-16 LRP1 agonist...
Opportunity to Partner Novel VHH Multi-Specific Antibodies Targeted at Solid and Hematologic Tumors
Our client, Starmab Biomed Inc (“Starmab” or the “Company”), is a US/China-based biotech company headquartered at Beijing Zhongguancun...
Zumutor – Licensing Opportunity for Next Generation Tumor-Directed Immunotherapeutics Harnessing the Power of NK Cells
Zumutor Biologics is a biotechnology company based in Boston, USA, and Bangalore, India, focused on advancing innovative cancer...
D-PLEX100 from Polypid for Prevention of Surgical Site Infections - Seeking a US Licensing Partner
Our client, PolyPid Ltd. ( PolyPid - Optimized Therapeutics ; NASDAQ:PYPD) has a patented surgical site infection (SSI) prevention...
Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification
Evecxia deploys 5-hydroxytryptophan, 5-HTP, to achieve Serotonin Synthesis Amplification. 5-HTP amplifies brain serotonin and have shown...
The Sage Group: 30 Years of Successful Bioscience Transactions
London and New York, September 1 2024 - The Sage Group ( www.sagehealthcare.com ), a leading global advisor in the bioscience sector,...
bottom of page